MacroGenics to Participate in Upcoming Investor Conference
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company specializing in antibody-based cancer therapies, has announced its participation in the H.C.
Rhea-AI Summary
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company specializing in antibody-based cancer therapies, has announced its participation in the H.C. Wainwright Global Investment Conference. The event will take place on May 25, 2022, in Miami, FL, where President & CEO Scott Koenig will provide a corporate overview at 11:30 am ET. The company will also conduct one-on-one meetings with investors. A webcast of the presentation will be available on MacroGenics' Investor Relations website for 30 days following the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – MGNX
The recorded move for MGNX in the trading session of this news was -9.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, MD, May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference in May 2022.
- H.C. Wainwright Global Investment Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate overview in Miami, FL, on Wednesday, May 25, 2022, at 11:30 am ET. Management will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.